Cargando…

Genetic screening for anticancer genes highlights FBLN5 as a synthetic lethal partner of MYC

BACKGROUND: When ectopically overexpressed, anticancer genes, such as TRAIL, PAR4 and ORCTL3, specifically destroy tumour cells without harming untransformed cells. Anticancer genes can not only serve as powerful tumour specific therapy tools but studying their mode of action can reveal mechanisms u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masood, Motasim, Ding, Qize, Cawte, Adam D., Rueda, David S., Grimm, Stefan W., Yagüe, Ernesto, El-Bahrawy, Mona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588048/ https://www.ncbi.nlm.nih.gov/pubmed/37864183 http://dx.doi.org/10.1186/s12964-023-01300-3

Ejemplares similares

TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease
por: Masood, Motasim, et al.
Publicado: (2020)

MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
por: Zhang, Tingting, et al.
Publicado: (2020)

Development of Synthetic Lethality Anticancer Therapeutics: Miniperspective
por: Fang, Bingliang
Publicado: (2014)

Clinical and Biological Significances of FBLN5 in Gastric Cancer
por: Bian, Xiulan, et al.
Publicado: (2023)

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
por: Borankova, Karolina, et al.
Publicado: (2023)

Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma
por: Li, Wei-Ming, et al.
Publicado: (2020)

Syn-Lethality: An Integrative Knowledge Base of Synthetic Lethality towards Discovery of Selective Anticancer Therapies
por: Li, Xue-juan, et al.
Publicado: (2014)

Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response
por: Kciuk, Mateusz, et al.
Publicado: (2022)

Adult-onset demyelinating neuropathy associated with FBLN5 gene mutation
por: Cheng, Si, et al.
Publicado: (2017)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells
por: Sun, Zhe, et al.
Publicado: (2022)

Methodological approaches in application of synthetic lethality screening towards anticancer therapy
por: Canaani, D
Publicado: (2009)

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening
por: Zhou, Zongxiang, et al.
Publicado: (2014)

Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network
por: Liu, Lei, et al.
Publicado: (2018)

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019)

New insight into clinical heterogeneity and inheritance diversity of FBLN5-related cutis laxa
por: Gharesouran, Jalal, et al.
Publicado: (2021)

Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways
por: Invrea, Federica, et al.
Publicado: (2021)

FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma
por: Li, Fubin, et al.
Publicado: (2017)

Discovery and validation of FBLN1 and ANT3 as potential biomarkers for early detection of cervical cancer
por: Hao, Yi, et al.
Publicado: (2021)

Genetic variants and haplotypes in fibulin-5 (FBLN5) are associated with pseudoexfoliation glaucoma but not with pseudoexfoliation syndrome
por: Kapuganti, Ramani Shyam, et al.
Publicado: (2023)

Novel Insights into RAD52’s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies
por: Balboni, Beatrice, et al.
Publicado: (2023)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens
por: Christodoulou, Eleni G., et al.
Publicado: (2017)

Synergistic effects of rare variants of ARHGAP31 and FBLN1 in vitro in terminal transverse limb defects
por: Tian, Hong, et al.
Publicado: (2022)

SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets
por: Guo, Jing, et al.
Publicado: (2016)

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma
por: Thng, Dexter Kai Hao, et al.
Publicado: (2022)

Live cell imaging of single RNA molecules with fluorogenic Mango II arrays
por: Cawte, Adam D., et al.
Publicado: (2020)

Characterization of a distinct lethal arteriopathy syndrome in twenty-two infants associated with an identical, novel mutation in FBLN4 gene, confirms fibulin-4 as a critical determinant of human vascular elastogenesis
por: Kappanayil, Mahesh, et al.
Publicado: (2012)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2
por: Mahadevan, Daruka, et al.
Publicado: (2014)

RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells
por: Hölzen, Lena, et al.
Publicado: (2022)

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
por: Li, Jie, et al.
Publicado: (2023)

miR-370-3p as a Novel Biomarker Promotes Breast Cancer Progression by Targeting FBLN5
por: Mao, Jiahui, et al.
Publicado: (2021)

Loss of enteric neuronal Ndrg4 promotes colorectal cancer via increased release of Nid1 and Fbln2
por: Vaes, Nathalie, et al.
Publicado: (2021)

Protease Addiction and Synthetic Lethality in Cancer
por: Freije, José M. P., et al.
Publicado: (2011)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7v593ln2r7evdvcakg4cbeqrq6